ECTRIMS

Why B-cell therapies, or why not?

3848 2300 Peter Stevenson, PhD

The rational for B-cell therapy in multiple sclerosis (MS) was presented during ECTRIMS 2019, with David Baker (Blizard Institute, Queen Mary University of London, UK) posing the question of why…

read more

Are stem cells in MS ready for prime time?

2300 1535 Peter Stevenson, PhD

Hot topics continued at ECTRIMS 2019 in Stockholm with Joachim Burman (Department of Neurology, Uppsala University Hospital, Sweden), who stepped up to the podium to discuss autologous haematopoietic stem cell transplantation (aHSCT)…

read more

Enough evidence for vitamin D in MS?

3450 2300 Peter Stevenson, PhD

The role of vitamin D in the treatment of multiple sclerosis (MS) took centre stage during the first day of ECTRIMS 2019 in Stockholm, Sweden. In a ‘Hot Topic’ session,…

read more

Cognitive impairment in MS

2048 1153 Mea Holm, PhD

Up to 70% of MS patients suffer from cognitive decline, which often has a profound impact on an individual’s quality of life. It is little surprise that MS researchers are…

read more

Serum neurofilament light: A biomarker for disease activity in MS

1920 1080 Mea Holm, PhD

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

read more

Results from the MS-SMART trial unveiled

3971 2975 Mea Holm, PhD

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

read more

De-risking PML: A conversation with Prof. Walter Atwood

2872 2598 Prof. Dr. Krassen Nedeltchev

We interviewed Professor Walter Atwood last week at the 2018 ECTRIMS congress in Berlin, Germany, to learn about advances in treating progressive multifocal leukoencephalopathy (PML) – an important treatment-associated infection…

read more

Fighting neurodegeneration in MS

3150 2100 Mea Holm, PhD

The pathology of multiple sclerosis (MS) involves not only the loss of myelin sheets around the axons of neurons, but also the fragmentation of the axons themselves. At ECTRIMS 2018,…

read more

MS treatment strategy: Hitting hard and early, or minimising risks through stepwise escalation?

1969 1525 Mea Holm, PhD

With more than a dozen approved treatment options for relapsing-remitting multiple sclerosis (RRMS), treatment decision making is an increasingly complex task for neurologists. At ECTRIMS 2018, the topic on which…

read more

FLOODLIGHT offers illuminating outcomes for smartphone monitoring in MS

1920 1080 Peter Stevenson, PhD

Smartphone-based, high-yield active and passive self-monitoring of multiple sclerosis (MS) may enhance clinical disease assessments when compared to conventional methods for detecting subtle progressive clinical changes, according to a study…

read more
Brainwork is supported by unrestricted grants from: